Characteristics of recipients of tixagevimab-cilgavimab (T/C) who developed COVID-19 infection between December 19, 2021 and July 31, 2022 when Omicron was the dominant circulating variant.
收藏NIAID Data Ecosystem2026-05-01 收录
数据链接：
官方服务：
资源简介：
Characteristics of T/C recipients who were infected prior to receiving T/C (pre-T/C) are compared with characteristics of T/C recipients who were diagnosed with COVID after having received any dose of T/C (post-T/C).
创建时间：
2023-04-27
